» Articles » PMID: 30709415

Effect of Financial Support on Reducing the Incidence of Catastrophic Costs Among Tuberculosis-affected Households in Indonesia: Eight Simulated Scenarios

Overview
Publisher Biomed Central
Date 2019 Feb 3
PMID 30709415
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The World Health Organization's End Tuberculosis Strategy states that no tuberculosis (TB)-affected households should endure catastrophic costs due to TB. To achieve this target, it is essential to provide adequate social protection. As only a few studies in many countries have evaluated social-protection programs to determine whether the target is being reached, we assessed the effect of financial support on reducing the incidence of catastrophic costs due to TB in Indonesia.

Methods: From July to September 2016, we interviewed adult patients receiving treatment for TB in 19 primary health centres in urban, sub-urban and rural area of Indonesia, and those receiving multidrug-resistant (MDR) TB treatment in an Indonesian national referral hospital. Based on the needs assessment, we developed eight scenarios for financial support. We assessed the effect of each simulated scenario by measuring reductions in the incidence of catastrophic costs.

Results: We analysed data of 282 TB and 64 MDR-TB patients. The incidences of catastrophic costs in affected households were 36 and 83%, respectively. Patients' primary needs for social protection were financial support to cover costs related to income loss, transportation, and food supplements. The optimum scenario, in which financial support would be provided for these three items, would reduce the respective incidences of catastrophic costs in TB and MDR-TB-affected households to 11 and 23%. The patients experiencing catastrophic costs in this scenario would, however, have to pay high remaining costs (median of USD 910; [interquartile range (IQR) 662] in the TB group, and USD 2613; [IQR 3442] in the MDR-TB group).

Conclusions: Indonesia's current level of social protection is not sufficient to mitigate the socioeconomic impact of TB. Financial support for income loss, transportation costs, and food-supplement costs will substantially reduce the incidence of catastrophic costs, but financial support alone will not be sufficient to achieve the target of 0% TB-affected households facing catastrophic costs. This would require innovative social-protection policies and higher levels of domestic and external funding.

Citing Articles

Effects of conditional cash transfers on tuberculosis incidence and mortality according to race, ethnicity and socioeconomic factors in the 100 Million Brazilian Cohort.

Jesus G, Gestal P, Silva A, Cavalcanti D, Lua I, Ichihara M Nat Med. 2025; 31(2):653-662.

PMID: 39753969 PMC: 11835739. DOI: 10.1038/s41591-024-03381-0.


Impact of financial support on treatment outcomes of multidrug-resistant tuberculosis: A population-based, retrospective cohort study in Shanghai, China.

Chen Y, Shen X, Zhang Y, Wu Z, Xu B, Chen J J Clin Tuberc Other Mycobact Dis. 2024; 37:100500.

PMID: 39691806 PMC: 11650311. DOI: 10.1016/j.jctube.2024.100500.


Determinant of catastrophic costs associated with treatment for rifampicin-resistant TB in households in the Republic of Moldova.

Ciobanu A, Plesca V, Doltu S, Manea M, Domente L, Dadu A IJTLD Open. 2024; 1(6):266-273.

PMID: 39021450 PMC: 11249656. DOI: 10.5588/ijtldopen.23.0608.


Access of people with pulmonary tuberculosis to government programs: Primary Care professionals' perceptions.

Lima H, Sodre V, Souza C, Cardoso M, Cavalheiro Maymone Goncalves C, Nogueira L Rev Bras Enferm. 2024; 76Suppl 2(Suppl 2):e20220716.

PMID: 38558031 PMC: 10642008. DOI: 10.1590/0034-7167-2022-0716.


Economic burden of multidrug-resistant tuberculosis on patients and households: a global systematic review and meta-analysis.

Akalu T, Clements A, Wolde H, Alene K Sci Rep. 2023; 13(1):22361.

PMID: 38102144 PMC: 10724290. DOI: 10.1038/s41598-023-47094-9.


References
1.
Martins N, Morris P, Kelly P . Food incentives to improve completion of tuberculosis treatment: randomised controlled trial in Dili, Timor-Leste. BMJ. 2009; 339:b4248. PMC: 2767482. DOI: 10.1136/bmj.b4248. View

2.
Daftary A, Padayatchi N . Social constraints to TB/HIV healthcare: accounts from coinfected patients in South Africa. AIDS Care. 2012; 24(12):1480-6. PMC: 3484188. DOI: 10.1080/09540121.2012.672719. View

3.
Oxlade O, Murray M . Tuberculosis and poverty: why are the poor at greater risk in India?. PLoS One. 2012; 7(11):e47533. PMC: 3501509. DOI: 10.1371/journal.pone.0047533. View

4.
Mauch V, Bonsu F, Gyapong M, Awini E, Suarez P, Marcelino B . Free tuberculosis diagnosis and treatment are not enough: patient cost evidence from three continents. Int J Tuberc Lung Dis. 2013; 17(3):381-7. DOI: 10.5588/ijtld.12.0368. View

5.
Lutge E, Lewin S, Volmink J, Friedman I, Lombard C . Economic support to improve tuberculosis treatment outcomes in South Africa: a pragmatic cluster-randomized controlled trial. Trials. 2013; 14:154. PMC: 3680200. DOI: 10.1186/1745-6215-14-154. View